The ABC(DE) of ADTs in Advanced Prostate Cancer



Date & Location
Tuesday, March 1, 2022, 12:00 PM - Tuesday, February 28, 2023, 11:59 PM

Credits
AMA PRA Category 1 Credits™ (1.00 hours), AMA PRA Category 1 Credits™ Designated (1.00 hours)

Target Audience
Specialties - Oncology, Radiation Oncology, Urology
Professions - Non-Physician, Nurse, Nurse Practitioner, Other Healthcare Professionals, Pharmacist, Physician, Physician Assistant/Associate, Physicians In Training, Resident Physician

Overview

Prostate cancer is the most common cancer in men in the U.S., responsible for an estimated 248,530 new cases and 34,130 deaths in 2021. For patients diagnosed with advanced prostate cancer, androgen deprivation therapy (ADT) plays a major role in treatment but may be associated with a broad range of adverse effects. Of these, increased risk of cardiovascular (CV) events is among the most serious, as cardiovascular disease (CVD) is the most common non-cancer cause of death in patients with prostate cancer.

For physicians providing care to patients with advanced prostate cancer, staying current on the factors associated with safe, effective ADT use—indications for use, CVD risks, and comparative clinical efficacy of ADT agents—is essential. Of particular importance is the incorporation of the ABCDE algorithm (awareness, blood pressure monitoring, cholesterol management and cigarette avoidance, diet and diabetes, and exercise) into the advanced prostate cancer management paradigm to help prevent and manage CVD in patients with advanced prostate cancer who are receiving ADT.

Developed for urologists, oncologists, and radiation oncologists, this Virtual Practice uses a hands-on, case-based approach to discussing recommended considerations and strategies for managing CVD risk and optimizing outcomes when providing ADT to patients with advanced prostate cancer.


Registration

There are no fees for participating in and receiving CME credit for this online activity.

This activity can be accessed using the following url: https://education.redmeded.com/a/RGGKVR

For technical questions related to this activity, please contact RedMedEd at 610.251.6841 or [email protected].
For questions regarding CME credit, contact the University of Cincinnati at [email protected].


Objectives
As a result of participating in this activity, participants should be able to:

  1. Evaluate patient CVD risk and cardiovascular safety data when selecting ADT for patients with advanced prostate cancer;
  2. Evaluate the clinical efficacy of gonadotropin-releasing hormone (GnRH) agonists and antagonists in the setting of advanced prostate cancer.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and RedMedEd. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Additional Information

Disclosure of Ineligible Relationships (COI) Policy

In accordance with the ACCME Standards for Integrity and Independence and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies (commercial interest) within the last 24-months. The ACCME requires us to disqualify individuals who refuse to provide this information from involvement in the planning and implementation of accredited continuing education. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence.

Program Planners

RedMedEd
The RedMedEd planners have disclosed no relevant financial relationships.

University of Cincinnati Continuing Medical Education Office
The University faculty and planners have disclosed no relevant financial relationships.

Robert Ellis, MD, Professor, Physician Reviewer
Heather Muskopf, CME Program Manager
Susan P. Tyler, PhD, Associate Dean

Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. RedMedEd, the University of Cincinnati, and Pfizer Inc and Myovant Sciences Ltd do not recommend the use of any agent outside the labeled indications.

Disclaimer
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of RedMedEd, the University of Cincinnati, or Pfizer Inc and Myovant Sciences Ltd. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.